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The Ob gene, which is known to encode the 16 kDa 
protein hormone leptin, is one of the main genes that 
has been linked to the obesity phenotype in humans. 
Examination of Ob gene expression, as well as leptin’s 
mode of action in the hypothalamus through an 
intracellular signaling cascade, reveals the complexities 
of weight regulation (Friedman & Halaas, 1998). Single 
point mutations in the Ob gene can produce 
nonfunctional leptin protein due to the disruption of key 
intramolecular features, resulting in a chronic obesity 
phenotype (Farooqi et al., 1998; Hager et al., 1998). 
Current modes of therapy being explored include gene 
therapy using recombinant adenoviruses, which serve 
as vectors for leptin cDNA, as well as direct leptin 
injections (Friedman & Halaas, 1998). While both 
approaches to correcting leptin deficiency have 
shortcomings and require further research to improve 
their effectiveness, they demonstrate potential means of 
correcting specific metabolic disorders. Such 
breakthroughs are essential, given the prevalence of 
obesity in the United States alone and the health threat 
obesity poses by increasing predisposition to other life 





One of the most prevalent health issues that continues to 
affect a growing number of Americans in the twenty-first 
century is obesity. To be considered overweight, an 
individual must have a BMI of 25-29.9, while an obese 
individual has a BMI ≥ 30; these designations are 
determined based on weight ranges that are greater than 
what is generally considered healthy for a given height (Pi-
Sunyer, 2002; Ogden et al., 2008). With the rise of fast food, 
television, video games, and lifestyles that either promote 
sedentary tendencies or leave little time for tending to one’s 
personal health, it is no wonder that over the past 50 years 
the number of overweight and obese individuals has risen to 
64% of adults and 25 million children in the U.S. (Ogden et 
al., 2008). Along with the societal stigmatism of being obese 
and the limitations it poses for an individual in his or her 
ability to participate in certain activities, a number of other 
health conditions can result, such as coronary heart disease, 
type II diabetes, cancer (including endometrial, breast, and 
colon), hypertension, dyslipidemia, stroke, liver disease, 
gallbladder disease, sleep apnea, respiratory problems 
(asthma), osteoarthritis, and reproductive problems in 
women (abnormal menses and infertility) (Pi-Sunyer, 2002; 
Ogden et al., 2008). Therefore, the exploration of different 
means to combat obesity has been brought to the forefront 
of medicine over the past decade.  
As reported by Pi-Sunyer (2002), obesity not only 
has an environmental/behavioral component (60-70%) but a 
genetic component (30-40%) as well. When obesity is the  
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result of environmental/behavioral influences, it is possible to 
reverse the effects with drastic changes in lifestyle. 
However, for individuals that are genetically predisposed to 
weight gain, it is more difficult to control body mass.  
According to the most recent update of the 
Obesity Gene Map, which examined the genetic mutations 
associated with 176 varying cases of obesity, there are 11 
different genes that have been linked to weight gain and fat 
retention (Rankinen et al., 2006). One of the most well 
known is the obesity (Ob) gene located on chromosome 7, 
which codes for the “satiety hormone” leptin (Friedman & 
Halaas, 1998). Leptin is a 16 kDa protein hormone secreted 
at high levels by white adipose tissue and at low levels in 
gastric epithelium and the placenta (Friedman & Halaas, 
1998). It appears to aid in the regulation of energy intake 
and expenditure by curbing appetite and speeding up 
metabolism (Friedman & Halaas, 1998). When genetic 
mutations result in abnormal, nonfunctional leptin, individuals 
have a tendency to gain weight. Therefore, understanding 
how leptin functions is crucial to understanding one of the 
common genetic factors that can lead to obesity. 
 
The Discovery of Leptin 
 
Before much research had been completed on the causes of 
obesity and the discovery of leptin, three main theories 
existed regarding the way in which the body could potentially 
regulate body weight: a thermoregulation theory, where 
maintenance of a basal body temperature through energy 
expenditure influences weight; a glucostatic theory, where 
plasma glucose regulates all energy stores; and a lipostatic 
theory, where a product of fat metabolism circulates in the 
blood and interacts with certain receptors to either burn or 
maintain fat stores (Castracane & Henson, 2007). Of the 
three theories, the lipostatic theory most closely resembles 
the manner in which leptin functions as a peripheral signal in 
a feedback loop system.  It was first proposed by Coleman 
(1978) through his studies on obesity and diabetes that the 
Ob gene encoded a hormone and the Db gene encoded its 
receptor. It was not until 1994, however, that Friedman’s lab 
at Rockefeller University was able to identify leptin as the 
product of the Ob gene and linked it back to obesity 
(Friedman, 1996; Castracane & Henson, 2007). Initially, 
Friedman et al. (1991) used positional cloning to verify the 
identity of the Ob gene and found that it encoded a 4.5 kB 
RNA sequence for the known protein hormone leptin.  
Using two strains of mutant mice that expressed a 
chronically obese phenotype, the ob/ob mouse (production 
of ineffective leptin protein) and the db/db mouse (production 
of ineffective leptin receptor), Friedman (1996) and his 
research team demonstrated that leptin directly influenced 
weight loss (Castracane & Henson, 2007). Specifically, the 
ob/ob mice were injected with recombinant mouse leptin, 
which reduced body weight by 40% after four weeks 
(Friedman, 1996). This was attributed to an observed 
reduction in food intake by the mice, as well as an increase 
in metabolism. Similarly, in wild type mice that were injected 
with recombinant mouse leptin, there was a sustained 12% 
weight loss (Friedman, 1996). This demonstrated that leptin 
served as a means to regulate body fat stores because 
reintroducing the functional leptin protein to mutant ob/ob 
mice essentially reversed the chronic obesity phenotype, 
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The Protein Hormone Leptin 
 
Leptin on the Genomic Level 
The Ob gene is exclusively expressed by white adipose 
tissue, as well as at low levels from gastric epithelium and 
placental tissue (Freidman & Halaas, 1998). Therefore, 
leptin is not produced in direct response to food ingestion. 
Rather, it appears to function in the long-term regulation of 
body weight (Friedman & Halaas, 1998). 
The Ob gene, located on band 31.3 of the long 
arm of chromosome 7, consists of three exons and two 
introns that span 18 kb pairs (Gong et al., 1996). 
Transcriptional regulation of the Ob gene consists of the 
complex interplay of promoter regions and regulatory 
elements in response to a number of hormones, proteins, 
and glucocorticoids. A TATA promoter is located 28 base 
pairs from the transcriptional start codon (Gong et al., 1996). 
Additionally, a C/EBP and CCAAT/enhancer binding protein 
region has been identified, along with a GRE, glucocorticoid 
response elements, and a CREB, cAMP response element-
binding protein (Gong et al., 1996). 
Of the proposed molecules that aid in 
transcriptional regulation, the role of dexamethasone, a 
glucocorticoid, and insulin have been most widely 
researched. As confirmed in several studies, transcription of 
the Ob gene is stimulated by dexamethasone, most likely 
due to its interaction with GRE regions of the gene (Bradley 
& Cheatham, 1999; Halleux et al., 1998). However, insulin 
has no effect on the transcriptional activity of the Ob gene 
(Bradley & Cheatham, 1999; Halleux et al., 1998). Additional 
information regarding the synthesis of leptin in its 
transcriptional and translational pathways is not currently 
known. However, it was noted by Cohen (1996) that leptin 
does not undergo any posttranslational modification because 
the relative mass of the functional protein is roughly equal to 
its proposed mass, based on the primary structure of the 167 
amino acid protein. 
Secretion of Leptin and its Role as an Afferent Signal in the 
CNS 
After mature leptin has been produced within adipose cells, 
some of the protein hormone is released to circulate at basal 
levels in the plasma and the rest is stored in the 
endoplasmic reticulum of these cells (Bradley & Cheatham, 
1999). Two molecules that stimulate the secretion of stored 
leptin from adipose cells are dexamethasone and insulin, 
both of which can elicit up to a twofold increase in leptin 
plasma levels (Bradley & Cheatham, 1999). 
Regardless of when leptin is secreted by adipose 
cells into the surrounding plasma, it initiates a response 
pathway by binding to leptin receptors, Ob-R, located 
primarily in different nuclear regions of the hypothalamus 
(Friedman & Halaas, 1998; Mercer et al., 1996; Spanswick 
et al. 1997). A study by Satoh et al.(1997) confirmed that the 
hypothalamus was an integral part of the leptin signaling 
pathway by comparing the phenotype of mice with 
hypothalamic lesions to ob/ob and db/db mice. Significant 
weight gain was observed in the mice with hypothalamic 
lesions (Satoh et al., 1997). This conclusion was additionally 
supported by the results obtained by Halaas et al. (1997), 
who injected mice both intracerebroventricularly and 
peripherally with leptin. A decrease in food intake was seen 
in mice injected intracerebroventricularly but not peripherally, 
and it took larger doses of peripherally administered leptin to 
achieve the same level of adipose tissue reduction (Halaas 
et al., 1997). These results indicate that the hypothalamic 
region in the brain is the main initiation site for leptin action. 
There are five alternatively spliced forms of the 
Ob-R gene, which result in different leptin receptors: Ob-Ra, 
Ob-Rb, Ob-Rc, Ob-Rd, and Ob-Re (Friedman & Halaas, 
1998). A member of the cytokine family, the leptin receptor 
protein has both an intracellular and extracellular region that 
includes two ligand binding domains (Friedman & Halaas, 
1998). Of the five isoforms of leptin receptors, the function of 
only Ob-Ra and Ob-Rb has been examined. Ob-Ra has 
been implicated in aiding in the transport of leptin across the 
blood-brain barrier, while Ob-Rb is the hypothalamic 
receptor leptin that binds to initiate signaling pathways to 
regulate body weight (Friedman & Halaas, 1998; Mercer et 
al., 1996; Spanswick et al. 1997).  
In order for the Ob-Rb receptor to become 
activated after leptin is bound, Jak2, an intracellular signaling 
kinase, must undergo phosphorylation (Friedman & Halaas, 
1998). Jak2 then actively phosphorylates STAT at a tyrosine 
residue, promoting dimerization of STAT monomers. This 
phosphorlyated STAT dimer is subsequently actively 
transported into the nucleus, where it binds to inducible 
promoter regions of specific genes to activate their 
transcription. In the leptin signaling pathway, neuropeptides, 
such as melanocyte stimulating hormone (MSH), 
melanocortin-4 receptor (MC-4), agouti-related transcript 
(ART), and corticotropin-releasing hormone (CRH), are 
transcribed (Friedman & Halaas, 1998; Mercer et al., 1996; 
Spanswick et al. 1997). These neuropeptides act to 
decrease food intake, increase energy expenditure through  
 
 
Figure 1 (Blue). Transcriptional signaling pathway of neuropeptides 




Figure 2 (Red). Flow diagram of biological response to differing leptin 
levels. (Figures modified from Friedman & Halaas, 1998.)  
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metabolic processes, and activate sympathetic nervous 
system function. Therefore, the end result of increased leptin 
levels ultimately is the reduction of body mass. 
Alternatively, in response to little or no leptin 
present in plasma, transcription of neuropeptide Y (NPY) 
and its receptor are upregulated through a similar signaling 
pathway (Friedman & Halaas, 1998). NPY, in turn, increases 
food intake, decreases energy expenditure by slowing 
metabolism, activates the parasympathetic nervous system, 
increases CRH, as well as decreases growth hormone 
releasing hormone and gonadotropin-releasing hormone 
(Friedman & Halaas, 1998).  Essentially, NPY functions to 
decrease the amount of energy expended by limiting growth 
and reproduction, while maintaining “resting state” body 
functions and increasing energy input. It is currently unclear 
why NPY is not transcriptionally activated when leptin is 
circulating at higher levels in the plasma. It has been 
suggested, however, that higher levels of leptin inhibit NPY 
or that other neuropeptides produced outweigh the effects of 
NPY (Friendman & Halaas, 1998). 
 
Mutations in Ob Gene Lead to Low Leptin Plasma Levels 
and Obesity 
 
Many cases of obesity are often related to the insensitivity of 
Ob-R receptors to plasma levels of leptin; however, 
mutations in the Ob gene can result in lower levels of 
functional leptin and lead to obesity in individuals as well. 
This observation was demonstrated by Ravussin et al. 
(1997) in linking chronic obesity in Pima Indians to low levels 
of leptin. While DNA analysis was not completed in this 
study to trace lower levels of leptin to a specific mutation in 
the Ob gene, other studies indicate that this phenotype can 
be attributed to recessive, autosomally-inherited mutations 
(Farooqi et al., 1998; Hager et al., 1998). 
 In one study conducted by Hager et al. (1998), a 
single point mutation (an adenine to guanine substitution) at 
position 19 on exon 1 of the Ob gene led to decreased levels 
of leptin in blood plasma, resulting in obesity. This mutation 
was seen in two separate Caucasian populations with a high 
rate of penetrance (Hager et al., 1998). In a separate study 
completed by Farooqi et al. (1998), a deletion of a guanine 
nucleotide was detected through genetic analysis in a 
number of test subjects. This deletion, in turn, disrupted the 
reading frame of the Ob gene so that 14 aberrant amino 
acids and a premature stop codon replaced the regular 
coding sequence in the resulting protein (Farooqi et al., 
1998). This mutant leptin protein lacked the C-terminal 
cysteine necessary for intramolecular disulfide binding. 
Thus, the mutant leptin protein hormone lacked any 
biological activity, causing the manifestation of the obesity 
phenotype. 
 
Treatments for Obesity by Increasing Leptin Levels 
 
Gene Therapy 
For individuals that experience a reduction in leptin levels 
due to mutations in the Ob gene that render the protein 
nonfunctional, the most direct means of increasing leptin is 
to alter its expression on the genomic level. The most 
promising approach in correcting metabolic disorders is 
through gene therapy using recombinant adenoviruses. 
Several studies have used these types of vectors to carry 
cDNA for leptin to induce hyperleptinemia in rats (Chen et 
al., 1996; Muzzin et al., 1996). In a study conducted by Chen 
et al. (1996), hyperleptinemia was induced in an 
experimental group of rats containing no leptin-related 
mutations. Throughout the experiment and at the end of 28 
days, plasma leptin levels, food intake, and weight gain/loss 
in relation to adipose tissue were examined in the 
experimental group of rats injected with the recombinant 
adenovirus. In rats expressing the recombinant leptin 
protein, leptin plasma levels were approximately four times 
greater than in control rats, which were normal in Ob gene 
expression and not injected with recombinant leptin (Chen et 
al., 1996). Chen et al. (1996) found that with an increase in 
leptin there was a 30-50% reduction in food intake, and on 
average there was only a 22 gram weight gain in 
adenovirus-infected rats in comparison to a 115-132 gram 
weight gain seen in control rats.  
 In a related experiment conducted by Muzzin et al. 
(1996), ob/ob mice were injected with the recombinant 
adenovirus expressing mouse leptin cDNA to examine 
whether the chronic obese phenotype could be reversed. 
Shortly after the administration of the recombinant 
adenovirus, a drastic reduction of food intake and weight 
was seen, as well as a normalization of insulin levels and 
glucose tolerance (Muzzin et al., 1996). After 2-3 weeks, 
when leptin levels began to decrease in the ob/ob mice 
injected with the recombinant adenovirus, the chronic obese 
phenotype resurfaced and mice increased their food intake, 
resulting in rapid weight gain (Muzzin et al., 1996). This 
occurrence verified that the functional adenovirus vector was 
effective in normalizing leptin levels. 
 The major disadvantage of this approach to 
therapy is that the duration of expression of adenovirally-
expressed genes is limited. This is likely caused by an 
immune response that destroys the genetic material of these 
vectors due to specific viral-encoded genes that initiate a 
host immune response (Chen et al., 1996; Muzzin et al., 
1996). Therefore, in the future, specific genes should be 
turned off to avoid the degradation of the vector. However, 
this approach to therapy seems promising because of the 
ability to correct both the obesity phenotype in ob/ob mice 
and the ability to return to the original obesity phenotype 
without any adverse effects (Muzzin et al., 1996). 
 
Direct Administration of Leptin Effectively Reverses Obesity 
Phenotype 
Increasing leptin levels through direct injections is another 
therapeutic method that has been examined in order to 
correct leptin deficiency as a result of mutations in the Ob 
gene (Christensen et al., 1999; Friedman & Halaas, 1998; 
Frühbeck, et al., 1998). Several studies have demonstrated 
that peripheral administration of leptin shows modest 
decreases in food intake, resulting in the reduction of 
adipose tissue mass. In one study conducted by Frühbeck, 
et al. (1998), ob/ob mice were injected intraperitoneally with 
doses of leptin. In comparison to ob/ob mice that did not 
receive the injection, the basal lipolytic activity was 
significantly increased to over 50% (Frühbeck, et al., 1998). 
 Using a larger animal model, the rhesus monkey, 
Christensen et al. (1999) compared the effectiveness of a 
peripheral versus a central injection of leptin. When leptin 
was administered peripherally, there was no observed 
decrease in food intake over the course of the three-day 
administration period (Christensen et al.,1999). However, 
when leptin was administered intracerebroventricularly, a 
sustained reduction of food intake (40-50%) was observed 
after day two of administration (Christensen et al.,1999). 
These findings suggest that centrally administered leptin is 
more effective in producing long-standing effects in the 
reduction of food intake. Similarly, in a clinical trial, subjects 
were given daily injections of leptin, and over the course of 
six months, a group of obese subjects lost 7.1kg in 
comparison to 1.7kg for a control group that was 
administered placebos (Friedman & Halaas, 1998). 
However, not all members of the obese group lost significant 
amounts of weight, indicating that peripheral leptin 
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administration is not always completely effective (Friedman 
& Halaas, 1998). 
As indicated by these studies, peripheral leptin 
administration is not always entirely effective, which stands 
in contrast to intracerebroventricular injections. However, it 
would be implausible to administer leptin directly into the 
brain given the risks it would impose on the individual. 
Therefore, to improve this approach to therapy, it would be 
pertinent to consider localized leptin solubility, as well as 
potential local reactions that could occur at the site of 
injection that would alter its effectiveness to create an 





Given the prevalence of obesity and the numerous negative 
health effects that are associated with this phenotype, it is 
pertinent to examine the pathway of leptin in order to 
determine effective treatment options. Leptin functions 
through a complex mechanism involving receptors present in 
specific hypothalamic regions, which means that therapy 
options must somehow manipulate this pathway in order to 
be effective. Current treatment options, including both gene 
therapy and direct leptin injections, have proven to be 
modestly successful. However, both approaches present 
serious drawbacks, which would require further research to 
be completed. For gene therapy, it is necessary to alter the 
expression of specific viral genes within the adenovirus 
vectors to ensure that they are not rapidly degraded within 
the target organism due to an immune response. In order for 
leptin injections to be effective without being directly 
administered into brain regions, modifications that do not 
change the functionality of the protein, but rather the 
efficiency of its transport mechanism to receptors in the 
hypothalamus, would be necessary. Both types of therapy, 
however, show movement in the right direction regarding the 
battle against genetic predispositions to obesity. 
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